The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
[1]   Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia [J].
Anderson, Kristin R. ;
Chambers, Carole R. ;
Lam, Nadine ;
Yau, Patrick S. ;
Cusano, Frances ;
Savoie, M. Lynn ;
Sheikh, Naureen .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) :19-25
[2]   Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil [J].
Silveira, C. A. P. ;
Daldegan, M. B. ;
Ferrari, I. .
GENETICS AND MOLECULAR RESEARCH, 2011, 10 (03) :2038-2048
[3]   Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase [J].
Ganta, Ranga Raman ;
Nasaka, Srividya ;
Gundeti, Sadashivudu .
INDIAN JOURNAL OF PEDIATRICS, 2016, 83 (09) :1009-1012
[4]   Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients [J].
Wu, Eric Q. ;
Johnson, Scott ;
Beaulieu, Nicolas ;
Arana, Mateo ;
Bollu, Vamsi ;
Guo, Amy ;
Coombs, John ;
Feng, Weiwei ;
Cortes, Jorge .
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) :61-69
[5]   Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia [J].
Hosoya, Kazuhisa ;
Mochinaga, Sakiko ;
Emoto, Akiko ;
Yokoo, Hiromi ;
Tokushima, Hideaki ;
Egoshi, Masayoshi ;
Sueoka-Aragane, Naoko ;
Kimura, Shinya .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (06) :1203-1210
[6]   Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia [J].
Alves, Alexandra Rodrigues ;
Lima, William Gustavo ;
Nagai, Michelly Martins ;
Vilela Rodrigues, Joao Paulo ;
Ayres, Lorena Rocha .
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 52 (04) :581-589
[7]   Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia [J].
Cole, Ashley L. ;
Jazowski, Shelley A. ;
Dusetzina, Stacie B. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (11) :1529-1533
[8]   Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar? [J].
Al-Dewik, N. Ader I. ;
Morsi, Hisham M. ;
Samara, Muthanna M. ;
Ghasoub, Rola S. ;
Gnanam, Cinquea C. ;
Bhaskaran, Subi K. ;
Nashwan, Abdulqadir J. ;
Al-Jurf, Rana M. ;
Ismail, Mohamed A. ;
AlSharshani, Mohammed M. ;
AlSayab, Ali A. ;
Ben-Omran, Tawfeg I. ;
Khatib, Rani B. ;
Yassin, Mohamed A. .
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 :95-104
[9]   Targeted treatment of chronic myeloid leukemia: role of imatinib [J].
Tamascar, Ila ;
Ramanarayanan, Jeyanthi .
ONCOTARGETS AND THERAPY, 2009, 2 :63-71
[10]   Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients [J].
Clark, Samantha E. ;
Marcum, Zachary A. ;
Radich, Jerry ;
Etzioni, Ruth ;
Basu, Anirban .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) :1343-1351